A Study in Japan of the Safety and Antiviral Activity With Chronic Hepatitis B Infection
Status:
Completed
Trial end date:
2005-02-01
Target enrollment:
Participant gender:
Summary
The objectives of this study are to demonstrate that entecavir has antiviral activity with
undetectable at Week 48, and to assess the safety and the pharmacokinetic in Japanese
patients given entecavir at each dose of 0.1 and 0.5 mg for 52 weeks